Reversible pulmonary arterial hypertension induced by bosutinib: a case report.

(ERJ open research, v11.3)

In patients with chronic myeloid leukaemia and no pre-existing dasatinib-induced cardiovascular complication, exposure to bosutinib may lead to severe pulmonary arterial hypertension that is potentially reversible upon cessation of treatment https://bit.ly/4fxCggY.

Copyright ©The authors 2025.

Read publication

Overview publication

TitleReversible pulmonary arterial hypertension induced by bosutinib: a case report.
Date2025-05-01
Issue nameERJ open research
Issue numberv11.3
DOI10.1183/23120541.00943-2024
PubMed40470146
AuthorsIvan J, Esnaud R, Orvain C, Khouri C, Chaumais MC, Humbert M, Montani D & Gagnadoux F
Read Read publication